The Paradoxical Activity of BRAF Inhibitors: Potential Use in Wound Healing

Overview

Journal Arch Dermatol Res

Date 2025 Jan 28

PMID 39873776

Authors

Sonali Karhana

Mohd Samim

Nidhi

Mohd Ashif Khan

Affiliations

Soon will be listed here.

Abstract

The area of wound healing presents a promising field of interest for clinicians as well as the scientific community. A major concern for physicians is the rising number of elderly people suffering from diabetes, leprosy, tuberculosis and the associated chronic wounds. While traditional therapies target basic wound care, innovative strategies that accelerate wound healing are needed. V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors are anti-cancer drugs used primarily for melanoma. They also exhibit paradoxical activity, a phenomenon characterized by unintended activation of the Mitogen-Activated Protein Kinase (MAPK) signalling pathway leading to skin hyperproliferation. Studies have demonstrated that BRAF inhibitors can be repurposed to accelerate the healing of acute and chronic wounds by exploiting their paradoxical activity. This review evaluates studies on BRAF inhibitors by employing a systematic search strategy using databases such as PubMed, Scopus, Google Scholar, and Web of Science. Articles were screened based on relevance to the paradoxical activity of BRAF inhibitors, their mechanisms, and applications in wound healing. Evidence from in vitro, in vivo, and clinical studies demonstrates that BRAF inhibitors can enhance processes such as epithelialization and angiogenesis, essential for wound repair. This review summarizes the reports on the paradoxical activity of BRAF inhibitors, the predicted mechanisms behind the paradoxical activity, and their potential use in wound healing.

References

Graves N, Phillips C, Harding K . A narrative review of the epidemiology and economics of chronic wounds. Br J Dermatol. 2021; 187(2):141-148. DOI: 10.1111/bjd.20692. View

Chetter I, Arundel C, Corbacho Martin B, Hewitt C, Fairhurst C, Joshi K . Negative pressure wound therapy versus usual care for surgical wounds healing by secondary intention (SWHSI-2 trial): study protocol for a pragmatic, multicentre, cross surgical specialty, randomised controlled trial. Trials. 2021; 22(1):739. PMC: 8543414. DOI: 10.1186/s13063-021-05662-2. View

Fernandes F, Arruda D, Santana G, Longo L, Cesar M, da Matta D . Morphological and ultrastructural changes in fungal agents after LASER application. Int J Dermatol. 2023; 63(2):217-223. DOI: 10.1111/ijd.16919. View

Romano V, Di Gennaro D, Sacco A, Festa E, Roscetto E, Basso M . Cell Toxicity Study of Antiseptic Solutions Containing Povidone-Iodine and Hydrogen Peroxide. Diagnostics (Basel). 2022; 12(8). PMC: 9407558. DOI: 10.3390/diagnostics12082021. View

Daher G, Choi K, Wells J, Goyal N . A Systematic Review of Oral Nutritional Supplement and Wound Healing. Ann Otol Rhinol Laryngol. 2022; 131(12):1358-1368. DOI: 10.1177/00034894211069437. View

Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

Pushpakom S, Iorio F, Eyers P, Jane Escott K, Hopper S, Wells A . Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2018; 18(1):41-58. DOI: 10.1038/nrd.2018.168. View

Escuin-Ordinas H, Li S, Xie M, Sun L, Hugo W, Huang R . Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. Nat Commun. 2016; 7:12348. PMC: 4974650. DOI: 10.1038/ncomms12348. View

Eyers P, Cohen P, Goedert M, Boyle F, Hewitt N, Plant H . Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol. 1999; 6(8):559-68. DOI: 10.1016/s1074-5521(99)80088-x. View

10.

Li H, Chen Y, Rao S, Chen X, Liu H, Qin J . Recent advances in the research and development of B-Raf inhibitors. Curr Med Chem. 2010; 17(16):1618-34. DOI: 10.2174/092986710791111242. View

11.

Agianian B, Gavathiotis E . Current Insights of BRAF Inhibitors in Cancer. J Med Chem. 2018; 61(14):5775-5793. DOI: 10.1021/acs.jmedchem.7b01306. View

12.

Escuin-Ordinas H, Liu Y, Sun L, Hugo W, Dimatteo R, Huang R . Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects. PLoS One. 2021; 16(6):e0252597. PMC: 8221471. DOI: 10.1371/journal.pone.0252597. View

13.

Tracy L, Minasian R, Caterson E . Extracellular Matrix and Dermal Fibroblast Function in the Healing Wound. Adv Wound Care (New Rochelle). 2016; 5(3):119-136. PMC: 4779293. DOI: 10.1089/wound.2014.0561. View

14.

Driskell R, Jahoda C, Chuong C, Watt F, Horsley V . Defining dermal adipose tissue. Exp Dermatol. 2014; 23(9):629-31. PMC: 4282701. DOI: 10.1111/exd.12450. View

15.

Thakur M, Connellan P, Deseo M, Morris C, Dixit V . Immunomodulatory Polysaccharide from Chlorophytum borivilianum Roots. Evid Based Complement Alternat Med. 2011; 2011:598521. PMC: 3136712. DOI: 10.1093/ecam/neq012. View

16.

Falanga V, Isseroff R, Soulika A, Romanelli M, Margolis D, Kapp S . Chronic wounds. Nat Rev Dis Primers. 2022; 8(1):50. PMC: 10352385. DOI: 10.1038/s41572-022-00377-3. View

17.

Singh V, Devgan L, Bhat S, Milner S . The pathogenesis of burn wound conversion. Ann Plast Surg. 2007; 59(1):109-15. DOI: 10.1097/01.sap.0000252065.90759.e6. View

18.

Crouzet C, Nguyen J, Ponticorvo A, Bernal N, Durkin A, Choi B . Acute discrimination between superficial-partial and deep-partial thickness burns in a preclinical model with laser speckle imaging. Burns. 2015; 41(5):1058-63. PMC: 4479308. DOI: 10.1016/j.burns.2014.11.018. View

19.

Gonzalez A, Costa T, Andrade Z, Medrado A . Wound healing - A literature review. An Bras Dermatol. 2016; 91(5):614-620. PMC: 5087220. DOI: 10.1590/abd1806-4841.20164741. View

20.

Zhao R, Liang H, Clarke E, Jackson C, Xue M . Inflammation in Chronic Wounds. Int J Mol Sci. 2016; 17(12). PMC: 5187885. DOI: 10.3390/ijms17122085. View